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Abstract 
Brittany M. Gallagher 
SEMI-SYNTHESIS OF A NOVEL LIBRARY OF ALKALOIDS AS POTENTIAL 
SELECTIVE ANALGESICS 
2017-2018 
Gustavo Moura-letts, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
 
 Semi-synthetic compounds are an important part of the therapeutic drug discovery 
process. The goals of the project were to synthesize different generations of matrine 
analogues in order to gain many opportunities to manipulate the core structure. The long-
term goal was, by manipulating the structure, the possibility to increase the biological 
activity of the original compound while also decreasing the toxicity. The first-generation 
matrine analogue allows for a synthesis similar to the Striker reaction producing 
aminonitriles. An alkyne coupling reaction was also possible with the modification, 
producing propargyl-amines. Both of the reactions resulted in the addition of a triple 
bond substituent to the final products; increasing complexity and making the products not 
easily metabolized in the body, therefore able reach the target of interest. The second-
generation matrine derivative was reacted with epoxides to produce amino alcohols. 
Aminonitriles, propargyl-amines, and amino alcohols are known to be backbones of 
therapeutic drug compounds. The compounds synthesized were later experimented on 
chronic myeloid leukemia (CML) cells, also in combination with the manufactured drug 
Imatinib, in order to inhibit the BCR-ABL kinase activity in the CML cell lines E255K 
and T315I.	 
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Chapter 1 
Matrine and Matrine Analogues 
Introduction 
  Alkaloids. Alkaloids are naturally occurring compounds produced by organisms 
such as bacteria, fungi, plants and animals.1 The compounds contain basic nitrogen atoms 
and have neutral to weakly acidic properties; alkaloids can contain atoms such as carbon, 
hydrogen, nitrogen, oxygen, sulfur, chlorine, bromine, and phosphorous.1 The 
compounds are used as starting points in drug discovery because of the wide range of 
pharmacological activities including, but not limited to, antimalarial, antiasthma, 
anticancer, cholinomimetic, vasodilatory, antiarrhythmic, analgesic, antibacterial, and 
antihyperglycemic.1 Commonly known alkaloids include morphine, strychnine, quinine, 
and ephedrine.2 Alkaloids can also have psychotropic and stimulant activities, 
recreational drugs, for example, cocaine, nicotine, and caffeine.2  
Medicinal plants containing alkaloids have been used as therapeutics since around 
2000 BC.3 Studies on these alkaloids began around 1804 by Friedrich Sertürner, a 
German chemist whom separated what he called morphium from opium.3 In German and 
other European languages morphium is still the term used, however was given the name 
morphine in the English and French language by the French physicist Joseph Louis Gay-
Lussac.3 French researchers Pierre Joseph Pelletier and Joseph Bienaime Caventou 
discovered strychnine in the year 1818 and quinine in 1820.4 Other Alkaloids discovered 
between 1817 and 1860 included xanthine, atropine, caffeine, coniine, nicotine, 
colchicine, sparteine, and cocaine.4 A German chemist Albert Ladenburg, in 1886, 
created the first complete synthesis of an alkaloid.4 The synthesis began by reacting 2-
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methylpyridine with acetaldehyde and then reducing the 2-propenyl pyridine product 
with sodium, otherwise known as coniine.5 In the 20th century spectroscopic and 
chromatographic methods were created which helped to quickly identify, by 2008, over 
12,000 alkaloids.5 
  Matrine. Therapeutic alkaloids sophoridine, sophoranol, oxymatrine, and matrine, 
as well as others, are found specifically in Sophora flavescens, which is the dried root of 
the Kun Shen plant.6 Large doses of the plant root are needed in order to work, however 
the root is known to have numerous of health benefits including the treatment of skin 
diseases, insomnia, diarrhea, high fever, irregular heart beat, hot hands and feet, urinary 
tract infection, hair loss, and Hepatitis B Virus, along with various other diseases, 
infections, and symptoms.6 The alkaloid fraction of the plant root is made up of about a 
twenty percent combination of oxymatrine and matrine.6 In 1998, the Institute for 
Traditional Medicine introduced the fractions as a tablet under the name of Oxymatrine, 
also known as White Tiger; the tablet was made available to doctors to use on patients.7 
The tablet did not have any reported side effects from use.7 In a clinical setting, the 
average dosage of the drug is 400-600 mg per day.7 In China, the compound is given by 
injection, however, in the west, the compounds are given orally because injection 
administration was not acceptable.7  The difference between receiving the medication 
orally rather than through injection is the oral tablet results in more of the oxymatrine 
converting to matrine, whereas the injection leads to higher levels of oxymatrine in the 
blood stream; it is not clear if one delivery method is more effective than the other.8 A 
capsule form has also been given and showed similar signs of the injected method.8  
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 According to cancer specialist Chang Minyi, “Sophora subprostrata works through 
stimulating the anticancer immune mechanism of the patient and reinforcing his 
resistance against the growth of the tumor.”9 Xu Xiangru and Jiang Jikai of the 
Congquing University of Medical Sciences published about anticancer activity of sophora 
alkaloids.9 They discussed pharmacology studies showing the alkaloids could inhibit 
growth of tumor cells directly and could also affect immune functions such as turning 
cancer cells into normal functioning white blood cells.9 Xiangru and Jikai also discussed, 
in a clinical setting the sophora alkaloids were used successfully in treating the side effect 
of the decrease of white blood cells, also known as leukopenia, caused by cancer 
chemotherapy or radiation therapy, and for treating cancers such as leukemia, uterine 
cervical cancer, esophageal, and laryngeal cancer.10-11  
Matrine (Figure 1), as stated previously, is a tetracyclo-quinolizidine alkaloid 
obtained from the Chinese sophora flavescens root.12 The herb was viewed as a medium-
grade drug where both the seeds and root are considered toxic in the China Botanical 
Illustration, however the plant alkaloids have medicinal properties when used properly in 
small dosages of 3-10 grams per treatment.13 The compound has been used in Chinese 
medicine for thousands of years in the treatment of liver diseases, cardiovascular 
diseases, asthma, and tumors.13 The drug is administered mostly through injection, 
however can also be dispensed through tablet or capsule forms. 
Matrine is also used as an analgesic or as a therapeutic against infection by 
pathogenic microorganisms.14 It has also been used to stimulate cell metabolism and 
normalize immune function.15 The mechanism of matrine is not exactly known, however, 
scientists believe cell arrest, inhibition of cell proliferation, and induction of apoptosis are 
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possible mechanisms for the anti-tumor activities seen in vitro and in vivo.15 The 
department of Oncology at the Hospital of Traditional Medicine conducted research to 
determine if using Matrine as therapy would hold anti-tumor effects on breast cancer 
cells, and how exactly this happened.15 The results showed death in three different types 
of cells, but there was less toxicity in the controlled cells.16 The possibility of down 
regulation of IKKβ expression is the possible mechanism of action with the results shown 
in western blot analysis.16  
Semisynthetic approaches. Prior to chemical modification techniques being 
developed, drugs were composed entirely of natural sources such as herbs, animal 
products, and inorganic material.17 Centuries later, now the active components are 
extracted from the natural sources, are structurally characterized, and synthesized in a 
laboratory.17 The laboratory semi-synthetic and total synthetic approaches can create 
more active, and higher tolerated drugs for consumers.17 Naturally derived compounds 
are semi-synthesized to increase the therapeutic properties such as metabolism rate, 
toxicity, and excretion.18 Anticancer compounds Topotecan and Irinotecan originate from 
naturally isolated Camptothecin through commercial synthesis; the drug Vinorelbine is 
produced from plant extracted Catharanthine for commercial production.18 Production of 
microbes of modified alkaloids shows possibility to speed up the semi-synthesis 
development of alkaloid-modified pharmaceuticals to deliver superior intermediates 
closer to the final products.18 
  Pharmacology of Matrine. There are 27 alkaloids, which have been isolated from 
the plant root; they are classified into groups including matrine-type alkaloids, cytisine-
type alkaloids, anagyrine-type alkaloids, and lupinine-type alkaloids.19 The matrine-type 
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alkaloids have been identified as the bioactive component contributing to 
pharmacological effects on cancers, hepatitis B and C, and cardiac diseases.19 Matrine is 
the most active of the alkaloids and is responsible for the antitumor, anticancer, 
antimicrobial, anti-inflammatory, and analgesic properties.19-23 In the pharmaceutical 
market, matrine and oxymatrine are the only two compounds required as standards of 
evaluation of drug quality; no less than 1.2 percent of combined content of the two 
compounds should be analyzed by HPLC.24 Over the years, TLC, HPLC, and capillary 
electrophoresis have been used as methods to monitor the compounds and control the 
quality isolated from the plant root.25 The type and size of the ring structure of the core 
scaffold has main impact on the therapeutic properties of the compound.26 The structure 
of matrine contains both a nitrogen infused ring and a beta lactam ring.27 Around 60 
percent of small molecule drugs contain a nitrogen heterocycle.28-32 The nitrogen 
heterocycle can be a structurally diverse component in therapeutics, as well as, hold 
responsibility as an essential factor of FDA approved pharmaceuticals.33 The beta lactam 
ring is seen in present day antibiotics.34 The ring results in tight bonding to the active site 
inhibiting enzyme activity and resulting in cell wall development.35 
Hypothesis  
  Can we perform molecular scaffold and functional group modifications towards 
tailoring the structure-activity relationships for Matrine.37 
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Results  
  First-generation analogue. In order to begin the experiments, the first step was 
to open the lactam ring of the matrine in order to keep the core structure (Figure 2); this 
produced a methyl ester derivative and also provided an activation point for the analogue 
reactions. The matrine analogue reaction began with 2,940 mg of the matrine dissolved in 
118.37 mL of concentrated hydrochloric acid (HCl); this reaction was refluxed for 48 
hours. The solution was dried and methanolic hydrogen chloride was added to the 
solution, it was then stirred at room temperature while being monitored by thin layer 
chromatography (TLC, 10% methanol in dichloromethane). Hydrolysis of the compound 
was not evident by TLC, infrared spectroscopy (IR), or nuclear magnetic resonance 
(NMR); therefore more HCl was added and the reaction had to reflux for an additional 48 
hours. 
The resulting solution was dried, and rinsed with methanol three times while 
being dried in between. The resulting paste residue was then suspended in minimal 
isopropyl alcohol and diethyl ether was added while the reaction was vigorously stirring. 
The resulting precipitate was filtered, washed with ether, and the supernatant was dried; 
the process was repeated until the presentation of the matrine methyl ester was a white 
solid. The end product was then confirmed by 1HNMR and 13CNMR and compared to 
matrine’s 1HNMR and 13CNMR spectra to ensure opening; the first generation matrine 
analogue was then used as the starting material moving forward without the need to 
further purify.  
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  Second-generation analogue. The second-generation matrine analogue was a 
functional group modification in order to create a matrine derivative alcohol (Figure 3). 
The resulting alcohol derivative was more stable than the methyl ester starting material, 
making it easier to work with. The resulting alcohol analogue was used as the starting 
material for the reactions, which produced amino alcohols in the epoxide opening 
analogue library. An oven dried three-neck round bottom flask with a stir bar and reflux 
condenser was flushed with argon and charged with 141.51 mL of 1M (molar), borane-
THF complex; the reaction was run under neat conditions. Matrine dihydrochloride was 
then added as a solid, under argon, in portions; the flask was heated and refluxed for 48 
hours. The resulting reaction was quenched with methanol, underwent acid base 
extraction with HCl and NaOH, the aqueous layer was extracted with DCM and the 
product was allowed to precipitate in ethyl acetate. The resulting product was then rinsed 
three times with methanol and dried. The product structure was confirmed through mass 
spectroscopy.  
  Thiomatrine. The thiomatrine compound (Figure 4) was synthesized by reacting 
the Lawesson’s reagent with matrine. The reaction was refluxed in THF and the carbonyl 
group was converted into the thiocarbonyl by Lawesson’s reagent.    
Conclusion  
  Semi-synthetic reactions are an important part of the therapeutic drug discovery 
process. Following the synthesis of the matrine generation analogues, many opportunities 
to manipulate the core structure with the long-term goal of increasing biological activity 
while decreasing toxicity were available. The first generation matrine analogue allows for 
a synthesis similar to the Striker reaction to occur, as well as, an alkyne coupling 
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reaction, adding triple bond substituents to the final product; this increases complexity 
and produces α-aminonitriles. The second-generation matrine analogue is easier to work 
with because the alcohol makes the structure less reactive than the methyl ester analogue. 
The second-generation matrine derivative was reacted with epoxides in order to produce 
amino alcohols. Both α-aminonitriles and amino alcohols are known to be backbones of 
therapeutic drug compounds. 
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Figure 1. Structure of matrine 
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Figure 2. First-generation matrine analogue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N OH
H H
H
O
	 11	
 
Figure 3. Second-generation matrine analogue 
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Figure 4. Structure of thiomatrine  
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Chapter 2 
Strecker Reaction for Matrine Analogue Library 
Introduction 
  Strecker reaction. Adolph Strecker coined the Strecker amino acid synthesis 
(Figure 5), in 1850.38 The one pot, two-step reaction is a huge advantage; the reaction is a 
simple and economical creation of racemic α-aminonitriles.39 The synthesis also saves 
time and resources by avoiding the separation and purification processes, resulting in 
increased percent yields of the final products.40 The components in the Strecker reaction 
include an aldehyde, an amine, and cyanide.41 During the Strecker reaction, the aldehyde 
is condensed with ammonia in the presence of cyanide in order to form an α-
aminonitrile.42 The α-aminonitrile can then used as an intermediate to further synthesize 
amino acids; the basis for proteins, peptides, and pharmaceuticals.43-46 A benefit of 
running the reaction, in such way, is the possibility of stereoselectivity.47 There has been 
considerable interest in asymmetric synthesis for active α-aminonitriles; these are the key 
building blocks in pharmaceuticals and other approaches including biocatalytic routes, 
and metal catalyzed hydrogenation of enamides.48 Asymmetric approaches are more 
desirable due to the use of imines followed by a nucleophilic addition of cyanide in the 
presence of a chiral catalyst.49-52 In order for this direction to occur, there is the need of 
another donor instead of cyanide, or an iminium system instead of an imine.53     
  Mechanism. The mechanism for the Strecker mechanism begins with the 
carbonyl group of the aldehyde being activated by acid; ammonia then condenses with 
the aldehyde to form an iminium intermediate.54 After proton exchange, water is cleaved 
from the iminium ion.54 Cyanide then adds as a nucleophile to the imine carbon, creating 
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an α-aminonitrile.54 In the study, the first generation matrine analogue was used in place 
of ammonia.55 Using an amine instead of ammonia changed the mechanism for the 
synthesis of the products.55 Formation of an imine by reacting the aldehyde with the 
amine, followed by hydrocyanation is an alternate synthesis to the one pot.55  
  Amino nitriles in pharmacology. The number of nitrile containing 
pharmaceuticals is increasing; there are over 30 drugs prescribed for a diverse range of 
therapeutics.56-57 In addition, more than 20 other nitrile-containing leads are in clinical 
development.56-57 The pattern of nitrile-containing pharmaceutical rise identifies the 
nitrile being a desirable pharmacophore in future drug discoveries.58-59 The functionality 
must be activated by an electron withdrawing group, and the electrophilic additions 
shown in amino nitriles, for diabetes and osteoporosis treatment, have a reversible 
electrophilic attack.58-59 In most cases, the nitrile group of these drugs is not metabolized 
by the body and is excreted without being altered.60                                                        
Our Study 
  The objective of the first generation analogue synthesis was to produce semi-
synthetic amino nitriles. The study began trialing different conditions to see which was 
able to work best for our components in order to produce the highest percent yield. 
Beginning with 25 mg scale reactions, a 1:1 ratio was used for starting material to 
aldehyde with 1 mL of cyanide (acetone cyanohydrin or hydrogen cyanide). The 
reactions ran under neat conditions at room temperature in a non-inert atmosphere for 24 
hours. After observations were made, more small-scale reactions ran with 1-
Methylpiperazine as the starting material to avoid consumption of the first generation 
starting material until the reaction was optimized. The ratio of aldehyde and cyanide was 
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increased to 2:3 respectfully; the laboratory had the most amount of sodium cyanide in 
stock, therefore this was the cyanide of choice moving forward, and 0.75 mL of methanol 
was used as the solvent. Once the reaction conditions were up to par, the reaction scale 
was increased to 50 mg, still using 1-Methylpiperazine as the starting material. After the 
reaction could be scaled up, the 50 mg reaction ran using the first generation matrine 
analogue. Reactions were experimented, letting the aldehyde react with the starting 
material for approximately 15 minutes before adding the sodium cyanide, it was 
determined this factor did not influence the outcome of the reaction. Finally, the reactions 
were scaled up to 100 mg with 3 mL of methanol solvent with the 1:2:3 equivalences of 
starting material to aldehyde to sodium cyanide. 
  Results. The variable in the reaction was our aldehyde. In order to acquire a 
broad-spectrum library of new compounds, both aromatic and aliphatic aldehydes were 
reacted. After assessing the products, it was concluded aldehydes containing carbon 
chains are more reactive in the formation of the amino nitriles. In the future we would 
like to extend the scope of the library towards determining the pharmacological 
properties of these scaffolds.  
All of the reactions from small-scale to large-scale were monitored under thin 
liquid chromatography (TLC) in a chamber of 4:1 ethyl acetate to methanol. All of the 
products from the large-scale reactions were confirmed through 1HNMR and 13CNMR. 
Resulting products and yields can be observed in Table 1. 
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Conclusion 
  Pharmaceutical therapeutics containing nitriles is on the rise; this creates interest 
in the development of this pharmacophore in drug discovery. The information the 
Strecker reaction provides in addition to the use of the first-generation matrine analogue, 
holds all the benefits from the known reaction with the added benefits of using a nitrile 
already known for therapeutic effects. The determination of the results for the project 
concluded aldehydes containing carbon chains are more reactive in the formation of the 
α-aminonitriles; the longer the carbon chain, the higher of a percent yield was obtained.  
In the future, we aim to extend the scope of the library towards determining the 
pharmacological properties of these scaffolds. 
 
 
 
 
 
 
 
 
 
 
 
 
	 17	
 
 
Figure 5. Strecker reaction mechanism 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
N OH
H H
O
O
HR
N
N OH
H H
O
N
N OH
H H
O
N
N OH
H H
O
N
N OH
H H
O
H
O
H
R
H2O RR
N
+
PT
NaCN
R
	 18	
 
 
     Table 1 
 First-Generation Analogue Modification Products  
 R Percent Yield  R Percent Yield 
 75.9 
 
41.9 
 
50.4 
 
36.7 
 47.6 
 
33.1 
 43.7 
     Note. For all reactions: starting material was first-generation matrine analogue; 100     
     mg scale reactions; 1:2:3 eq of starting material, aldehyde, NaCN respectively; 3 mL   
     of methanol; room temperature for 24 hours. 
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Chapter 3 
Alkyne Coupling for Matrine Analogue Library 
Introduction  
  Second-generation modification. The second-generation analogue modification 
was alkyne coupling reaction; during 2001 and 2002 three groups separately reported out 
results using this method.61 The synthesis is a multicomponent reaction involving an 
aldehyde, amine, and alkyne, undergoes direct dehydrative condensation, and advances 
using a metal catalyst.61 The reaction results in propargyl amines which are the backbone 
intermediates to many other compounds, including nitrogen containing active 
compounds, such as β-lactams, oxotremorine analogues, conformationally restricted 
peptides, isosteres, natural products, and therapeutic drug molecules.62-64 The use of 
alkynes is valuable in therapeutics because of the triple bond.64 The bond makes the 
compound hard for the body to metabolize, thus the therapeutic will reach the target of 
interest.65 Since alkynes are not metabolically liable, the potency of the drug intensifies, 
therefore after synthesizing the alkynes with the starting material, there is potential for an 
increase in the structure activity relationship (SAR) of the first-generation matrine 
analogue, as well as, the original matrine compound.65  
Mechanism. The alkyne coupling reaction synthesizes by the metal catalyst first 
activating the alkyne to make a metal acetylide.66 The amine and aldehyde then combine 
to create an imine intermediate.66 The imine then reacts with the acetylide through 
nucleophilic addition to form the resulting propargylamine and the metal catalyst is 
recovered.66  
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Our Study 
  The alkyne coupling reaction was used as the foundation for the second-
generation analogue modification. The study began with trialing different conditions to 
produce the highest percent yield. The 10 mg experiments were set to run overnight with 
various solvents; acetonitrile (ACN) 0.5 mL at 80oC and 55oC and 1 mL at 70oC, 
tetrahydrofuran (THF) 1.50 mL at 55oC, heptanes 0.80 mL at 55oC, and toluene 1.7-2.0 
mL at 95oC. Some of these small-scale reactions were synthesized in an inert atmosphere. 
The first-generation matrine analogue was used as the starting material, Phenylacetylene 
was used as the alkyne, and while determining the best conditions, 4-Chlorobenzaldehyde 
remained as the consistent aldehyde. Published research papers lead to beginning with a 
copper catalyst because copper catalyst precursors are cheap, readily available, less toxic, 
and have most reactivity.66 In the beginning stages, copper(I) iodide was the consistent 
catalyst. The equivalencies of the starting material, aldehyde, alkyne, and catalyst were 
adjusted accordingly through interpretations made during TLC analysis (chamber 4:1 
ethyl acetate to methanol) of each reaction. Various metal catalysts were trialed, 
including copper(II) acetate, iron(III) oxide, and zinc iodide (ZnI2), to determine which 
would help drive the reaction further.  
  Results. The reaction conditions used to scale up, to 50 mg, were determined to 
be 1:1:2:1 equivalence of starting material, aldehyde, alkyne, and catalyst respectfully. 
The solvent used moving forward was toluene (3 mL) at 100oC with zinc iodide as the 
catalyst, Phenylacetylene as the consistent alkyne, and various aldehydes. Both aliphatic 
(butyraldehyde and octylaldehyde getting below 10% yields) and aromatic aldehydes 
were reacted, however it was determined aromatic compounds reacted further than 
	 21	
aliphatic compounds. Moving forward we aim to extend the scope of the library towards 
determining the pharmacological properties of these scaffolds. 
 All of the products from the large-scale reactions were confirmed through 
1HNMR and 13CNMR. The products and percent yields can be observed in Table 2. 
Conclusion 
  The use of propargylamines is desirable in drug therapeutic discoveries. The use 
of the triple bond makes the compound not easily metabolized and therefore able reach 
the target of interest. The first-generation matrine analogue can be used as the amine 
starting material in order to synthesize a library of propargylamines. The observations 
made in the study concluded aromatic aldehydes are further reacted than aliphatic 
aldehydes. In the future, we aim to extend the scope of the library towards determining 
the pharmacological properties of these scaffolds. 
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     Table 2  
 Second-Generation Analogue Modifications  
R Percent Yield R Percent Yield 
 
98.2 
 
76.4 
 
96.2 
 
66.5 
 
80.3 
    Note. For all reactions: starting material was the first-generation matrine analogue; the    
    alkyne was phenylacetylene; ZnI2 catalyst; 100 mg scale reactions; 1:1:2:1 eq of  
    starting material, aldehyde, alkyne and catalyst respectively; 3 mL of toluene solvent;  
    100oC for 24 hours. 
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Chapter 4 
Epoxide Opening for Matrine Analogue Library 
Introduction  
  Epoxide. An epoxide is a highly reactive, nonpolar compound due to the ring 
strain.67 The bond angles of the three atoms in the ring are similar to that of an equilateral 
triangle; the carbon to oxygen sharp bonds result in the strain.67 Epoxides are beneficial 
in synthesizing amino alcohols.68 These alcohols can further be reacted and used as 
nucleophilic substitution, and the nitrogen infused ring can control the stereochemistry.69 
A benefit to synthesizing amino alcohols is chirality, this characteristic is important 
because it indicates optical activity, which can be used to determine different 
enantiomers.70 Approximately 25 percent of drugs on the market are racemates of 
synthetic chiral drugs.71 A downfall to racemic compounds is the two enantiomers of a 
chiral drug can differ in dosage, efficacy, side effects, use, bioavailability, metabolism 
rate, excretion, and toxicity.72 The single enantiomer form has the advantage of enhanced 
therapeutic activity with limiting side effects and increased selectivity.73 
  Mechanism. In the second-generation matrine analogue, the nitrogen atom in our 
secondary amine holds a lone pair of electrons.74 The lone pair makes for our starting 
material to act as a nucleophile in the reaction scheme (Figure 6), to donate these 
electrons to the electrophile in order to form a chemical bond.75 In the study, the 
electrophile is the epoxide; the electrons attack the least substituted carbon in the epoxide 
opening the ring, which allows the C-N bond to be formed in the product.76 
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Our Study   
  During the formation of the epoxide opening analogue library, the second-
generation matrine analogue was used as the nucleophile, to be reacted with various 
epoxides in order to produce amino alcohols.77 The reactions ran on a 50 mg scale with 
about 2 mL of acetonitrile. Due to the reactions not progressing enough, the solvent was 
changed to 1,4-Doxane in order to raise the temperature of the reaction. The reactions ran 
at 80oC (ACN) or 90oC (1,4-Dioxane) for 24 hours. The starting material was dissolved 
in the 2 mL of solvent and epoxide was then added at a 1:1.5 ratio respectively. The 
product was then compared to the starting material by TLC in a chamber of 4:1 ethyl 
acetate to DCM.  
The product was dried and then reconstituted in diethyl ether to separate 
unreacted epoxide from the product. The reconstituted solution was put into a separator 
funnel and a small amount of 6M hydrochloric acid (HCl) was added, this was the layer 
the organic product diffused into. After shaking the separator funnel vigorously, the HCl 
layer was extracted; an acid base reaction was next generated with sodium hydroxide 
(NaOH) until a pH of 11 was formed, and a small amount of deionized (DI) water was 
then added. The new basic solution was added into a second separator funnel and the 
organic product was extracted three times with ethyl acetate. The organic layer was dried 
with sodium sulfate (Na2SO4) and filtered into a round bottom through gravity filtration. 
The round bottom was then dried and reconstituted with chloroform (CHCl3), transferred 
to a tared vial, and then dried once more.  
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  Results. The results concluded there was not a difference in yields for aromatic or 
aliphatic epoxides. Once our dry products were acquired, the structures were confirmed 
through 1HNMR, 13CNMR, and IR. The products and yields can be observed in Table 
3.The study has produced a comprehensive library of matrine derived amino alcohols 
which allows for the efficient determination of the biological profile of the corresponding 
scaffold and potential development of selective therapeutics.  
Conclusion 
  Amino alcohols are beneficial in drug therapeutics due to the chirality of the 
compounds. Amino alcohols have showed potential in treating diabetes, tuberculosis, as 
well as forming other antibiotics. This study has produce a comprehensive library of 
matrine amine alcohols that would allow for the efficient determination of the biological 
profile of the corresponding scaffold and potential development of selective therapeutics.  
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Figure 6. Epoxide opening reaction mechanism 
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Table 3  
Epoxide Opening Reaction Products 
Epoxide Percent Yield Epoxide	 Percent Yield	
 
 
53.8 			
 
43.6	
 
 
46.8 	
 
42.6	
 
 
46.3 	
 
37.6	
 
 
45.3 	
 
35.2	
 Note. For all reactions: The starting material was the second-generation matrine    
 analogue; 50 mg scale reactions; 1:1.5 eq of starting material to aldehyde; 2 mL of 
 solvent; 80oC (ACN) or 90oC (1,4-Dioxane) for 24 hours. 
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Chapter 5 
Matrine Analogue Library Pharmacological Results 
Introduction 
          Chronic myelogenous leukemia. Chronic myelogenous leukemia (CML) is a form 
of cancer, predominantly occurring in adults, which originates in blood-forming cells of 
bone marrow.78-80 A change occurs forming the mutated BCR-ABL gene (Figure 7) 
during the beginning development of the myeloid cells.81-83 The cells begin to mature and 
divide without dying, crowding out other cells in the bone marrow and eventually 
overflow into the blood stream.83 Acute leukemia can also occur from the change of the 
CML cells.84-85 Studies are being done on CML in laboratories, and clinical trials, to 
discover drugs to help fight the mutated gene and cells.86-87 Currently, Imatinib is the 
main source of drug choice on the market to target the BCR-ABL gene.88 The drug is a 
tyrosine kinase inhibitor (TKI), which is a class of chemotherapy medication to inhibit 
enzyme tyrosine kinase.89 The form of therapy allows for target treatment of certain 
cancers, decreasing the potential of damaging healthy cells to increase success.90 Studies 
are being done to see if drugs, such as Imatinib, will give better results if combined with 
another form of therapy such as chemotherapy, interferon, cancer vaccines, or other 
potential drugs.91-93 One study showed enhanced results when combining Imatinib with 
interferon; however this combination increased side effects.94 More studies are currently 
running to see if the combination of dasatinib, nilotinib, cyclosporine, or 
hydroxychloroquine can be more beneficial when combined with various TKIs.95-98  
     As stated previously, Sophora subprostrata [sophora alkaloids] work through 
stimulating the anticancer immune mechanism strengthening the patients fight against the 
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tumor.99 Pharmacology studies show alkaloids could inhibit growth of tumor cells 
directly.101 Recent reports claim matrine has potential to make leukemia cells transform 
into normal white blood cells.102 Matrine is also used as an analgesic or as a therapeutic 
against infection by pathogenic microorganisms; it has also been used to stimulate cell 
metabolism and normalize immune function.103 The mechanism of matrine is not exactly 
known, however, scientists believe cell arrest, inhibition of cell proliferation, and 
induction of apoptosis are possible for the anti-tumor activities seen in vitro and in 
vivo.104 
Results 
          The first and second-generation analogues of matrine, as well as various 
compounds from the modification libraries were experimented to see if the compounds 
could be identified as inhibitors on CML cells containing the E255K and T315I BCR-
ABL mutation with decreased toxicity.105 The derived compounds were tested in 
comparison and combination to drugs known to be therapeutics to CML patients such as 
Imatinib.106 
          The MTT assay showed a decrease in CML cell activity after 24 hours at 3.2 mM 
when exposed to matrine and the first-generation matrine analogue; thiomatrine had some 
effects, however not up to par with the matrine and matrine analogues.107 Annexin V/PI 
assay was used to confirm the results of the MTT assay; survival of the CML cells were 
decreased at 4mM.108 An analogue from the first-generation analogue library, AMA3 
(Figure 8), decreased the survival percentage of the CML cell survival at 40 nM and 400 
µM. The second-generation matrine analogue did not increase apoptosis in the cell line. 
Two compounds of the second-generation analogue library, 156 (Figure 9) and 159 
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(Figure 10), were effective in the E255K cell line when combined with Imatinib.108 The 
compounds decreased the capability of the T315I cells but were above the toxicity 
observed in the control, NIH3T3 and Ba/F3, lines.  
          Western blot analysis determined the combination treatment of 156 and Imatinib 
decreased the phosphorylation of Tyr412 on the BCR-ABL mutation cell lines of E255K, 
however this was not observed in the T315I line; this data was consistent with flow 
cytometric analysis.109   
           Structure activity relationship. The known compound in the study, Imatinib, 
compares to the structures synthesized by all structures containing nitrogen 
heterocycles.110,111 Imatinib is the main therapeutic used in patients with CML, however 
the T315I cell line is resistant to the drug; this is also the cause for around 15 percent of 
CML patient relapses.112-115 Matrine and the first generation matrine analogue, alone, did 
not show much activity until 4 mM. Compound AMA3 did show cell death beginning at 
40 nM. Aside from high concentrations of the synthesized compounds being used, the 
structures combined with Imatinib were able to increase the therapeutic effects in the 
cancer cell lines. Imatinib started showing some effects in P210 cell line at 1 µM, E255K 
cell line at 4µM, and was completely resistant to T315I cells, as expected. Combining 
Imatinib with structure 156 increased the death rate of the cancer cell lines while 
allowing the healthy cells to mostly survive, however Imatinib worked better alone than 
with compound 159 which was more toxic.  
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Conclusion  
          Aside from the high concentrations tested thus far, there is potential for the 
products to work on the cell lines if the concentration can be decreased. Further analysis 
is needed to determine if caspase-independent apoptotic mechanism are induced due to 
caspase-8 and caspase-3 activation not being detectable. 
Future 
          Compounds throughout the analogue libraries will continue to be analyzed to find 
an effective therapeutic for the T315I BCR-ABL mutated cells. The concentrations need 
to be further optimized in order to decrease the concentrations of the drug molecules in 
order to be considered for treatment in vivo studies.  
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Figure 7. BCR-ABL mutated gene 
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Figure 8. AMA3 compound 
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Figure 9. Product of reaction 156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N OHH
H H
HO
	 35	
 
Figure 10. Product of reaction 159 
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Experimental 
 
 
4-(2-(2-hydroxy-3-(4-methoxyphenoxy)propyl)decahydro-1H,4H-pyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)butan-1-ol. 1H NMR (400 MHz, Chloroform-d) δ 7.02 (s, 1H), 
6.89 – 6.75 (m, 3H), 4.10 – 3.84 (m, 2H), 3.73 (s, 2H), 3.59 (tt, J = 6.2, 4.3 Hz, 4H), 3.26 
– 3.03 (m, 3H), 3.00 – 2.68 (m, 6H), 2.57 (ddd, J = 29.9, 12.3, 4.2 Hz, 2H), 2.04 (dt, J = 
13.2, 2.3 Hz, 2H), 1.98 – 1.81 (m, 5H), 1.68 (dq, J = 13.0, 4.2 Hz, 2H), 1.67 – 1.52 (m, 
2H), 1.50 (tdd, J = 13.0, 6.3, 3.3 Hz, 4H), 1.48 – 1.23 (m, 10H), 1.27 – 1.12 (m, 2H). 13C 
NMR (101 MHz, Chloroform-d) δ 115.48 , 115.47 , 114.56 , 71.39 , 71.09 , 66.24 , 65.49 
, 64.58 , 64.49 , 64.05 , 62.31 , 62.14 , 61.97 , 57.62 , 57.51 , 57.45 , 57.25 , 57.23 , 57.15 
, 57.02 , 55.68 , 54.26 , 52.47 , 51.85 , 50.33 , 46.22 , 41.88 , 41.86 , 38.94 , 37.21 , 37.19 
, 37.08 , 34.87 , 32.86 , 32.69 , 32.57 , 31.36 , 29.66 , 28.65 , 28.40 , 28.20 , 28.15 , 27.96 
, 27.38 , 27.20 , 26.78 , 21.58 , 21.55 , 21.45 , 21.38 , 21.32 , 21.23 , 21.08 , 20.83 , 19.64. 
 
 
4-(2-(2-(4-bromophenyl)-2-hydroxyethyl)decahydro-1H,4H-pyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)butan-1-ol. 1H NMR (400 MHz, Chloroform-d) δ 7.42 (ddd, J 
= 7.9, 4.9, 2.7 Hz, 4H), 7.35 – 7.16 (m, 3H), 4.67 (dt, J = 10.8, 3.5 Hz, 1H), 3.66 – 3.44 
(m, 7H), 3.30 – 3.00 (m, 6H), 2.86 – 2.63 (m, 9H), 2.62 – 2.51 (m, 2H), 2.30 – 2.19 (m, 
1H), 2.07 – 1.91 (m, 4H), 1.86 (dddd, J = 18.3, 9.8, 7.8, 3.8 Hz, 8H), 1.83 – 1.63 (m, 2H), 
1.68 – 1.59 (m, 2H), 1.63 – 1.50 (m, 2H), 1.48 (qd, J = 7.6, 7.0, 3.6 Hz, 8H), 1.47 – 1.27 
(m, 7H), 1.22 (s, 1H), 1.31 – 1.10 (m, 3H). 
 
 
2-(1-(4-hydroxybutyl)octahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-2(3H)-
yl)cyclohexan-1-ol.1H NMR (400 MHz, Chloroform-d) δ 3.59 (tt, J = 5.0, 2.5 Hz, 2H), 
3.20 (dd, J = 13.1, 11.1 Hz, 1H), 3.08 (td, J = 9.5, 2.9 Hz, 1H), 2.84 – 2.70 (m, 2H), 2.60 
(dd, J = 11.9, 4.3 Hz, 1H), 2.09 – 1.98 (m, 1H), 2.02 – 1.82 (m, 3H), 1.78 – 1.55 (m, 2H), 
1.59 – 1.43 (m, 2H), 1.35 (s, 3H), 1.46 – 1.12 (m, 4H).t 13C NMR (101 MHz, 
Chloroform-d) δ 64.52 , 62.12 , 57.62 , 57.51 , 51.82 , 46.24 , 41.92 , 37.26 , 32.89 , 
32.69 , 32.62 , 28.16 , 26.79 , 24.36 , 21.55 , 21.47 , 21.33 , 21.24 . 
 
 
3-(1-(4-hydroxybutyl)octahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-2(3H)-yl)-
2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol. 1H NMR (400 MHz, Chloroform-d) δ 4.08 – 
3.93 (m, 1H), 3.60 (td, J = 6.2, 1.9 Hz, 6H), 3.23 (d, J = 12.1 Hz, 2H), 3.22 – 3.07 (m, 
2H), 3.12 – 3.04 (m, 2H), 2.84 – 2.70 (m, 6H), 2.61 (dd, J = 11.9, 4.3 Hz, 3H), 2.14 – 
1.99 (m, 4H), 2.03 – 1.90 (m, 2H), 1.94 – 1.79 (m, 8H), 1.80 – 1.39 (m, 19H), 1.43 – 1.07 
(m, 22H), 0.80 (s, 1H). 13C NMR (101 MHz, Chloroform-d) δ 134.50 , 125.08 , 77.22 , 
76.98 , 72.07 , 68.39 , 64.48 , 62.11 , 57.61 , 57.50 , 51.87 , 46.21 , 44.05 , 41.85 , 39.63 , 
38.84 , 37.19 , 34.35 , 32.72 , 32.65 , 32.51 , 29.66 , 28.15 , 27.75 , 27.72 , 27.47 , 27.22 , 
27.08 , 26.78 , 26.36 , 26.12 , 26.08 , 21.54 , 21.28 , 21.22 , 20.87 , 19.84 . 
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4-(2-(2-hydroxy-3-phenoxypropyl)decahydro-1H,4H-pyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)butan-1-ol.1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.22 
(m, 5H), 6.98 – 6.87 (m, 6H), 4.15 – 3.92 (m, 6H), 3.61 (ddd, J = 7.9, 6.2, 4.1 Hz, 7H), 
3.29 – 3.08 (m, 5H), 2.99 (dd, J = 12.5, 10.3 Hz, 1H), 2.92 – 2.71 (m, 7H), 2.69 – 2.51 
(m, 4H), 2.43 (dd, J = 13.0, 9.0 Hz, 1H), 2.28 (dd, J = 12.5, 3.7 Hz, 1H), 2.12 – 1.99 (m, 
5H), 1.98 – 1.87 (m, 6H), 1.91 – 1.83 (m, 3H), 1.87 – 1.72 (m, 2H), 1.72 (dt, J = 8.5, 4.2 
Hz, 2H), 1.71 – 1.53 (m, 6H), 1.51 (ddt, J = 13.8, 9.6, 5.4 Hz, 10H), 1.49 – 1.35 (m, 2H), 
1.39 (s, 7H), 1.36 (s, 4H), 1.39 – 1.25 (m, 3H), 1.29 – 1.16 (m, 3H), 1.24 (s, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 129.48 , 129.40 , 120.86 , 114.53 , 76.94 , 70.54 , 
70.26 , 66.12 , 65.38 , 64.58 , 64.36 , 64.04 , 62.45 , 62.22 , 62.09 , 57.59 , 57.50 , 57.48 , 
57.42 , 57.26 , 57.23 , 57.16 , 57.02 , 54.23 , 52.45 , 51.93 , 51.83 , 50.20 , 46.09 , 41.69 , 
38.94 , 37.04 , 36.99 , 34.90 , 32.84 , 32.63 , 32.59 , 32.34 , 31.29 , 29.69 , 28.60 , 28.33 , 
28.21 , 28.10 , 27.95 , 27.39 , 27.21 , 26.76 , 21.59 , 21.51 , 21.45 , 21.39 , 21.23 , 21.19 , 
21.08 , 20.80 , 19.56 . 
 
 
4-(2-(2-(4-chlorophenyl)-2-hydroxyethyl)decahydro-1H,4H-pyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)butan-1-ol. 1H NMR (400 MHz, Chloroform-d) δ 7.29 (s, 
1H), 7.37 – 7.18 (m, 1H), 3.71 – 3.49 (m, 3H), 3.30 – 3.05 (m, 2H), 2.94 (s, 4H), 2.88 – 
2.68 (m, 3H), 2.60 (dt, J = 11.9, 4.7 Hz, 1H), 2.10 – 1.99 (m, 1H), 1.99 – 1.82 (m, 3H), 
1.80 – 1.44 (m, 5H), 1.39 (s, 1H), 1.27 (tddd, J = 27.3, 18.1, 8.2, 4.4 Hz, 4H). 13C NMR 
(101 MHz, Chloroform-d) δ 128.52 , 128.44 , 127.45 , 127.13 , 77.20 , 73.84 , 68.93 , 
68.29 , 67.95 , 64.63 , 64.42 , 64.00 , 62.57 , 62.30 , 62.27 , 60.30 , 57.60 , 57.49 , 57.38 , 
57.25 , 57.20 , 56.97 , 56.89 , 52.25 , 51.85 , 51.27 , 46.14 , 41.84 , 39.16 , 37.14 , 36.79 , 
35.09 , 32.97 , 32.69 , 32.57 , 32.44 , 31.41 , 30.76 , 29.68 , 28.53 , 28.49 , 28.23 , 28.12 , 
27.93 , 27.41 , 27.17 , 26.78 , 21.52 , 21.40 , 21.28 , 21.24 , 21.21 , 20.99 , 20.94 , 19.75 . 
 
 
4-(2-(3-(furan-2-ylmethoxy)-2-hydroxypropyl)decahydro-1H,4H-pyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)butan-1-ol.1H NMR (400 MHz, Chloroform-d) δ 7.38 (s, 2H), 
6.35 – 6.27 (m, 4H), 4.49 (s, 1H), 4.48 (s, 3H), 3.92 – 3.80 (m, 2H), 3.60 (dd, J = 10.9, 
4.6 Hz, 5H), 3.56 – 3.37 (m, 4H), 3.12 (t, J = 13.0 Hz, 1H), 2.93 – 2.79 (m, 1H), 2.82 – 
2.67 (m, 8H), 2.63 – 2.49 (m, 2H), 2.32 (dd, J = 13.1, 9.8 Hz, 1H), 2.18 – 2.06 (m, 1H), 
2.05 – 1.88 (m, 14H), 1.92 – 1.78 (m, 4H), 1.64 (d, J = 10.0 Hz, 1H), 1.51 – 1.41 (m, 
3H), 1.39 (s, 6H), 1.36 (d, J = 8.1 Hz, 3H), 1.33 – 1.16 (m, 3H), 0.83 (s, 1H). 13C NMR 
(101 MHz, Chloroform-d) δ 151.65 , 142.89 , 142.72 , 116.34 , 110.23 , 109.55 , 109.40 , 
109.38 , 76.79 , 72.75 , 72.33 , 70.53 , 66.55 , 65.92 , 65.25 , 65.23 , 65.01 , 64.44 , 63.93 
, 62.31 , 61.82 , 61.74 , 57.44 , 57.36 , 57.32 , 57.20 , 57.16 , 54.27 , 52.45 , 51.68 , 50.17 
, 45.18 , 44.28 , 38.79 , 36.86 , 34.68 , 32.58 , 32.48 , 32.19 , 31.00 , 29.66 , 28.49 , 28.11 
, 27.82 , 27.31 , 27.12 , 21.51 , 21.35 , 21.32 , 21.02 , 20.99 , 20.87 , 19.46 , 1.85 . 
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